Cargando…
The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod
BACKGROUND: Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of patients with relapsing forms of multiple sclerosis (RMS). Fingolimod sequesters lymphocytes within lymphoid tissue thereby reducing the counts of circulating lymphocytes. However, fingolimod’s effects on the...
Autores principales: | Cohen, Jeffrey A, Bar-Or, Amit, Cree, Bruce A C, Mao-Draayer, Yang, Han, May H, Singer, Barry, Jannu, Ann, Kolodny, Scott, Meng, Xiangyi, Winger, Ryan C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318720/ https://www.ncbi.nlm.nih.gov/pubmed/30637116 http://dx.doi.org/10.1177/2055217318819245 |
Ejemplares similares
-
Immune cell subset profiling in multiple sclerosis after fingolimod
initiation and continued treatment: The FLUENT study
por: Mao-Draayer, Yang, et al.
Publicado: (2022) -
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015) -
Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis
por: Ghadiri, Mahtab, et al.
Publicado: (2020) -
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
por: Cree, Bruce A. C., et al.
Publicado: (2021) -
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
por: Fox, Edward J., et al.
Publicado: (2019)